For the nearly 200,000 women in the United States who will be diagnosed with breast cancer this year, the most important consideration is eradication. In Signe, we propose a four-part program to eradicate breast cancer. For some women, eradication means eliminating localized disease. Signe is developing a new non-toxic method based on direct application of a soluble form of iron that kills early forms of breast cancer. For other women, eradication means destroying cancer that has moved from the breast to other locations in the body. This is disseminated or metastatic breast cancer. Today, even with the best treatments, metastatic breast cancer has a poor prognosis. Signe plans a number of new therapies based on nutritional work done in serum-free defined cell culture with breast cancer cells. This will be the core of Signe's personalized medicine approach to treating breast and other cancers. In addition, a new previously unrecognized breast cancer gene has been identified. Its identification is a breakthrough. Until now, the only breast cancer genes known were BRCA1 and BRCA2. The problem has been that they are important for only 1 of 400 women in this country. The real issue is that 70% or more of breast cancers have no known genetic origin. The new gene shows "allelic imbalances" in 75% of breast cancers. It is a likely candidate for understanding the 70% of breast cancers not explained today. Screening of this gene will be a significant breakthrough. This gene is also a candidate for a new gene therapy for disseminated breast cancer. Although this discussion focuses on breast cancer, similar technology can be applied to prostate and other mucosal cancers. Indeed, mucosal cancers are 80% of the total malignancies in humans.